Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
‘Slender Man’ attacker back in custody. What we know about Morgan Geyser's disappearance and what happens next. - 2How food assistance programs can feed families and nourish their dignity
- 3How to disinfect if the stomach bug hits your home
- 4Involved Vehicles for Seniors: Track down the Best Picks for Solace and Dependability
- 5Experience Is standing by: 10 Pleasant Setting up camp Areas to
- PA accuses Israel of 'human trafficking' after planeload of Gazans arrives in South Africa
- Finding Your Motivation: Moves toward a Satisfying Life
- Scientists detect X-ray glow from interstellar comet 3I/ATLAS extending 250,000 miles into space
- Relentless rise in carbon pollution from fossil fuels slightly dampens climate-fighting hopes
- The Force of Systems administration: Individual Examples of overcoming adversity
- Nutrient Rich Natural products: Lift Your Wellbeing
- The most effective method to Amplify Your Opportunity for growth in a Web-based Degree Program
- Hamas demanded displaced Gazans pay rent on beach tents amid torrential downpour, IDF reveals
- Well informed: How to Take full advantage of Your Gadgets
